Roles of regulatory T cells in cancer immunity

International Immunology

Volumn 28, Issue 8, 2016, Pages 401-409

  Takeuchi, Yoshiko ^a   Nishikawa, Hiroyoshi ^a,b  

^a National Cancer Center   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Immune checkpoint inhibitors; Immune suppression; Treg targeted therapy

Indexed keywords

BIOLOGICAL MARKER; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR4; IMMUNOMODULATING AGENT; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3; CANCER VACCINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); GENE MUTATION; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTIC INFILTRATION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASM; PROCEDURES; TUMOR ESCAPE;

CANCER VACCINES; CD8 ANTIGENS; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSION; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE;

EID: 84988946035     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxw025     Document Type: Article

References (103)

1. + T regulatory cells. Nat. Immunol. 4:337.
2. Hori, S., Nomura, T. and Sakaguchi, S. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057.
3. Fontenot, J. D., Gavin, M. A. and Rudensky, A. Y. 2003. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4:330.
4. Sakaguchi, S., Sakaguchi, N., Asano, M. et al. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes variouss autoimmune diseases. J. Immunol. 155:1151.
5. Bennett, C. L., Christie, J., Ramsdell, F. et al. 2001. Thse immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27:20.
6. Wildin, R. S., Ramsdell, F., Peake, J. et al. 2001. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. 27:18.
7. Brunkow, M. E., Jeffery, E. W., Hjerrild, K. A. et al. 2001. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27:68.
8. Sakaguchi, S., Miyara, M., Costantino, C. M. and Hafler, D. A. 2010. FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol. 10:490.
9. Wing, K. and Sakaguchi, S. 2010. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat. Immunol. 11:7.
10. Shimizu, J., Yamazaki, S. and Sakaguchi, S. 1999. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163:5211.
11. Nishikawa, H. and Sakaguchi, S. 2014. Regulatory T cells in cancer immunotherapy. Curr. Opin. Immunol. 27:1.
12. Hodi, F. S., O'Day, S. J., McDermott, D. F. et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363:711.
13. Topalian, S. L., Hodi, F. S., Brahmer, J. R. et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366:2443.
14. Topalian, S. L., Sznol, M., McDermott, D. F. et al. 2014. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32:1020.
15. Robert, C., Long, G. V., Brady, B. et al. 2015. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372:320.
16. Hamid, O., Robert, C., Daud, A. et al. 2013. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369:134.
17. Robert, C., Schachter, J., Long, G. V. et al. 2015. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372:2521.
18. Rizvi, N. A., Mazières, J., Planchard, D. et al. 2015. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 16:257.
19. Brahmer, J., Reckamp, K. L., Baas, P. et al. 2015. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373:123.
20. Borghaei, H., Paz-Ares, L., Horn, L. et al. 2015. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373:1627.
21. Brahmer, J. R., Drake, C. G., Wollner, I. et al. 2010. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28:3167.
22. Brahmer, J. R., Tykodi, S. S., Chow, L. Q. et al. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366:2455.
23. Powles, T., Eder, J. P., Fine, G. D. et al. 2014. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558.
24. Ansell, S. M., Lesokhin, A. M., Borrello, I. et al. 2015. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372:311.
25. Larkin, J., Chiarion-Sileni, V., Gonzalez, R. et al. 2015. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373:23.
26. Chapman, P. B., D'Angelo, S. P. and Wolchok, J. D. 2015. Rapid eradication of a bulky melanoma mass with one dose of immunotherapy. N. Engl. J. Med. 372:2073.
27. Postow, M. A., Chesney, J., Pavlick, A. C. et al. 2015. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372:2006.
28. Topalian, S. L., Drake, C. G. and Pardoll, D. M. 2015. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27:450.
29. Rizvi, N. A., Hellmann, M. D., Snyder, A. et al. 2015. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124.
30. Snyder, A., Makarov, V., Merghoub, T. et al. 2014. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371:2189.
31. Van Allen, E. M., Miao, D., Schilling, B. et al. 2015. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 350:207.
32. Le, D. T., Uram, J. N., Wang, H. et al. 2015. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N. Engl. J. Med. 372:2509.
33. Matsushita, H., Vesely, M. D., Koboldt, D. C. et al. 2012. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482:400.
34. Gubin, M. M., Zhang, X., Schuster, H. et al. 2014. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515:577.
35. + T cells with an anergic phenotype in healthy individuals. Science 346:1536.
36. Adeegbe, D. O. and Nishikawa, H. 2013. Natural and induced T regulatory cells in cancer. Front. Immunol. 4:190.
37. Boyman, O. and Sprent, J. 2012. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 12:180.
38. Malchow, S., Leventhal, D. S., Nishi, S. et al. 2013. Aire-dependent thymic development of tumor-associated regulatory T cells. Science 339:1219.
39. + regulatory T cells induced by an agonist self-peptide. Nat. Immunol. 2:301.
40. Coombes, J. L., Siddiqui, K. R., Arancibia-Cárcamo, C. V. et al. 2007. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-ß and retinoic acid-dependent mechanism. J. Exp. Med. 204:1757.
41. + cells. Proc. Natl Acad. Sci. USA 102:4103.
42. +FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 110:2983.
43. Ellis, G. I., Reneer, M. C., Vélez-Ortega, A. C., McCool, A. and Martí, F. 2012. Generation of induced regulatory T cells from primary human naïve and memory T cells. J. Vis. Exp. 62:3738.
44. Hsu, P., Santner-Nanan, B., Hu, M. et al. 2015. IL-10 potentiates differentiation of human induced regulatory T cells via STAT3 and Foxo1. J. Immunol. 195:3665.
45. + T reg cells. J. Exp. Med. 203:1701.
46. Seddiki, N., Santner-Nanan, B., Martinson, J. et al. 2006. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med. 203:1693.
47. Mazzucchelli, R. and Durum, S. K. 2007. Interleukin-7 receptor expression: intelligent design. Nat. Rev. Immunol. 7:144.
48. Miyara, M., Yoshioka, Y., Kitoh, A. et al. 2009. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30:899.
49. + regulatory T cell function. Science 322:271.
50. + naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 10:1969.
51. Thornton, A. M. and Shevach, E. M. 1998. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188:287.
52. Walker, L. S. and Sansom, D. M. 2011. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat. Rev. Immunol. 11:852.
53. Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T. and Nakayama, E. 1999. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 59:3128.
54. + cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J. Exp. Med. 201:779.
55. Turk, M. J., Guevara-Patiño, J. A., Rizzuto, G. A., Engelhorn, M. E., Sakaguchi, S. and Houghton, A. N. 2004. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200:771.
56. Fridman, W. H., Pagès, F., Sautès-Fridman, C. and Galon, J. 2012. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12:298.
57. Sato, E., Olson, S. H., Ahn, J. et al. 2005. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl Acad. Sci. USA 102:18538.
58. Saito, T., Nishikawa, H., Wada, H. et al. 2016. Two FOXP3+CD4+ T-cell subpopulations distinctly control the prognosis of colorectal cancers. Nat. Med. in press.
59. Gobert, M., Treilleux, I., Bendriss-Vermare, N. et al. 2009. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 69:2000.
60. Svensson, H., Olofsson, V., Lundin, S. et al. 2012. Accumulation of CCR4?CTLA-4hi FOXP3?CD25hi regulatory T cells in colon adenocarcinomas correlate to reduced activation of conventional T cells. PLoS One 7:e30695.
61. + regulatory T cells, affect the survival of patients with oral squamous cell carcinoma. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 109:744.
62. Ishida, T., Ishii, T., Inagaki, A. et al. 2006. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res. 66:5716.
63. Curiel, T. J., Coukos, G., Zou, L. et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10:942.
64. Facciabene, A., Peng, X., Hagemann, I. S. et al. 2011. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Nature 475:226.
65. + T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res. 67:7487.
66. Tan, M. C., Goedegebuure, P. S., Belt, B. A. et al. 2009. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J. Immunol. 182:1746.
67. Spranger, S., Spaapen, R. M., Zha, Y. et al. 2013. Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci. Transl. Med. 5:200ra116.
68. Jaafar, F., Righi, E., Lindstrom, V. et al. 2009. Correlation of CXCL12 expression and FoxP3+ cell infiltration with human papillomavirus infection and clinicopathological progression of cervical cancer. Am. J. Pathol. 175:1525.
69. Redjimi, N., Raffin, C., Raimbaud, I. et al. 2012. CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity. Cancer Res. 72:4351.
70. Liu, J., Zhang, N., Li, Q. et al. 2011. Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. PLoS One 6:e19495.
71. Schlecker, E., Stojanovic, A., Eisen, C. et al. 2012. Tumorinfiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J. Immunol. 189:5602.
72. Sugiyama, D., Nishikawa, H., Maeda, Y. et al. 2013. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc. Natl Acad. Sci. USA 110:17945.
73. Tan, W., Zhang, W., Strasner, A. et al. 2011. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470:548.
74. Ghiringhelli, F., Puig, P. E., Roux, S. et al. 2005. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med. 202:919.
75. Nishikawa, H., Kato, T., Tawara, I. et al. 2005. Definition of target antigens for naturally occurring CD4+ CD25+ regulatory T cells. J. Exp. Med. 201:681.
76. Hindley, J. P., Ferreira, C., Jones, E. et al. 2011. Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors. Cancer Res. 71:736.
77. Sainz-Perez, A., Lim, A., Lemercier, B. and Leclerc, C. 2012. The T-cell receptor repertoire of tumor-infiltrating regulatory T lymphocytes is skewed toward public sequences. Cancer Res. 72:3557.
78. Fourcade, J., Sun, Z., Kudela, P. et al. 2010. Human tumor antigenspecific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire. J. Immunol. 184:6709.
79. Vence, L., Palucka, A. K., Fay, J. W. et al. 2007. Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 104:20884.
80. Wang, H. Y., Lee, D. A., Peng, G. et al. 2004. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 20:107.
81. Wang, H. Y., Peng, G., Guo, Z., Shevach, E. M. and Wang, R. F. 2005. Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. J. Immunol. 174:2661.
82. Bonertz, A., Weitz, J., Pietsch, D. H. et al. 2009. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J. Clin. Invest. 119:3311.
83. + regulatory T cells: implications for immunotherapy. Cancer Res. 68:6350.
84. + CD4 Treg depletion by infusion of a humanized anti-CCR4 antibody, KW-0761, in cancer patients. Clin. Cancer Res. 21:4327.
85. Shimizu, J., Yamazaki, S., Takahashi, T. et al. 2002. Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol. 3:135.
86. Jensen, S. M., Maston, L. D., Gough, M. J. et al. 2010. Signaling through OX40 enhances antitumor immunity. Semin. Oncol. 37:524.
87. Griseri, T., Asquith, M., Thompson, C. and Powrie, F. 2010. OX40 is required for regulatory T cell-mediated control of colitis. J. Exp. Med. 207:699.
88. Hirschhorn-Cymerman, D., Rizzuto, G. A., Merghoub, T. et al. 2009. OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J. Exp. Med. 206:1103.
89. Schaer, D. A., Cohen, A. D. and Wolchok, J. D. 2010. Anti-GITR antibodies - potential clinical applications for tumor immunotherapy. Curr. Opin. Investig. Drugs 206:1378.
90. Schaer, D. A., Budhu, S., Liu, C. et al. 2013. GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. Cancer Immunol. Res. 1:320.
91. Bulliard, Y., Jolicoeur, R., Zhang, J. et al. 2014. OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy. Immunol. Cell Biol. 92:475.
92. Curti, B. D., Kovacsovics-Bankowski, M., Morris, N. et al. 2013. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 73:7189.
93. Mitsui, J., Nishikawa, H., Muraoka, D. et a. 2010. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin. Cancer Res. 16:2781.
94. Bulliard, Y., Jolicoeur, R., Windman, M. et al. 2013. Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J. Exp. Med. 210:1685.
95. Cohen, A. D., Schaer, D. A., Liu, C. et al. 2010. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One 5:e10436.
96. Ali, K., Soond, D. R., Piñeiro, R. et al. 2014. Inactivation of PI(3) K p110d breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 510:407.
97. Jacobs, J. F., Punt, C. J., Lesterhuis, W. J. et al. 2010. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin. Cancer Res. 16:5067.
98. Rech, A. J., Mick, R., Martin, S. et al. 2012. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci. Transl. Med. 4:134ra62.
99. Walter, S., Weinschenk, T., Stenzl, A. et al. 2012. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 18:1254.
100. Simpson, T. R., Li, F., Montalvo-Ortiz, W. et al. 2013. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med 210:1695.
101. Selby, M. J., Engelhardt, J. J., Quigley, M. et al. 2013. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res. 1:32.
102. Matheu, M. P., Othy, S., Greenberg, M. L. et al. 2015. Imaging regulatory T cell dynamics and CTLA4-mediated suppression of T cell priming. Nat. Commun. 6:6219.
103. + T cells. J. Immunol. 194:5801.